Latest News

3 Things You Should Know About Unresectable NSCLC
3 Things You Should Know About Unresectable NSCLC

April 21st 2025

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

April 20th 2025

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.
Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer

April 19th 2025

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.
Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

April 18th 2025

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

April 18th 2025

More News